A Phase 4 interventional study of anidulafungin and voriconazole in Aspergillosis and Candidemia, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-02-09.
Sponsored by Pfizer · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.
Among the 17 studies testing voriconazole in Aspergillosis, this one is the 8th largest by enrollment, is one of 3 that started in 2008, is one of 4 in phase 4, and was the 10th registered.
134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.
Browse Aspergillosis studies →None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 1997; this study’s year is marked. 3 started in 2008.
This study's enrollment of 24 is below the median of 47 across 75 interventional studies indexed under Aspergillosis.
Median enrollment 24 across the 17 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
11 studies in Aspergillosis by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Aspergillosis by Pfizer, this one is one of 3 that started in 2008, is one of 3 in phase 4, and was the 7th registered.
Pfizer’s Aspergillosis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Aspergillosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 11 in Aspergillosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: anidulafungin and voriconazole
Drug pages: Anidulafungin · Voriconazole
Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
Plasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
Cmax = maximum observed plasma concentration; measured in micrograms per milliliter (ug/mL). Observed directly from the data. Collected on Day 3.
Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Plasma PK: Time to Reach Maximum Plasma Concentration (Tmax)
Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. Collected on Day 3.
Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Plasma PK: Area Under the Curve From Time Zero to Time = Tau (AUCtau)
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole; measured as micrograms times hours per milliliter (ug\*hr/mL). Collected on Day 3.
Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Plasma PK: Plasma Elimination Half-life (t1/2)
t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Collected on Day 3.
Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Plasma PK: Total Clearance (CL Total)
CL total = total clearance calculated as dose divided by AUCt; measured as milliliters per minute (mL/min). Collected on Day 3.
Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Plasma PK: Volume of Distribution at Steady-state (Vss)
Vss = volume of distribution at steady-state; measured as liters (L). Calculated as (CL multiplied by mean residence time extrapolated to infinity \[MRTinf\]). MRTinf = \[(AUMCt plus t (AUCinf minus AUCt)) divided by AUCt\] minus (infusion time divided by 2); AUMCt = area under the first moment curve from time zero to time t; AUCinf = area under the plasma concentration-time curve extrapolated to infinity.
Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Epithelial Lining Fluid (ELF) PK: Cmax
Cmax=maximum observed plasma concentration. ELF collected by bronchoscopy and bronchoalveolar lavage (BAL) Day 3; determined from BAL sample using urea dilution method: \[Drug ELF\]=\[Drug BAL\] multiplied by \[Urea SERUM\] divided by \[Urea BAL\]. Drug ELF=anidulafungin or voriconazole (drug) concentration in ELF corrected for dilution; Drug BAL=assayed drug concentration in BAL; Urea SERUM and Urea BAL simultaneously collected. Summary parameters derived using average data for all subjects; associated to a single subject for reporting purposes (mean with standard deviation not calculated).
Time frame: 4, 8, 12, 24 hours after start of infusion
ELF PK: Tmax
Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. ELF collected by bronchoscopy and BAL on Day 3.
Time frame: 4, 8, 12, 24 hours after start of infusion
ELF PK: AUCtau
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. ELF collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
Time frame: 4, 8, 12, 24 hours after start of infusion
ELF PK: t1/2
t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. ELF collected by bronchoscopy and BAL on Day 3.
Time frame: 4, 8, 12, 24 hours after start of infusion
Alveolar Macrophages (AM): Cmax
Cmax = maximum observed plasma concentration; observed directly from the data. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
Time frame: 4, 8, 12, 24 hours after start of infusion
AM: Tmax
Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. AM collected by bronchoscopy and BAL on Day 3.
Time frame: 4, 8, 12, 24 hours after start of infusion
AM: AUCtau
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
Time frame: 4, 8, 12, 24 hours after start of infusion
AM: t1/2
t1/2 = terminal elimination half-life in hours; Loge(2)Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AM collected by bronchoscopy and BAL on Day 3.
Time frame: 4, 8, 12, 24 hours after start of infusion
Overall Drug Penetration Ratio in ELF
ELF collected by bronchoscopy and BAL on Day 3. ELF to plasma penetration ratio calculated by dividing area under the plasma concentration-time profile (AUC) in ELF by AUC in plasma from 20 subjects where t is 24 hours for anidulafungin and 12 hours for voriconazole. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
Time frame: 4, 8, 12, 24 hours after start of infusion
Concentration Ratio in ELF to Plasma
Concentration ratio in ELF to plasma determined by a point estimate within each subject at the time-point where ELF data was available.
Time frame: 4, 8, 12, 24 hours after start of infusion
| Milestone | Anidulafungin and Voriconazole |
|---|---|
| Started | 24 |
| Subjects treated | 21 |
| Completed | 20 |
| Not completed | 4 |
| Withdrew: Did not meet entrance criteria | 3 |
| Withdrew: Adverse event | 1 |
Cmax = maximum observed plasma concentration; measured in micrograms per milliliter (ug/mL). Observed directly from the data. Collected on Day 3.
| ug/mL | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 6.56 ± 1.62 |
| Voriconazole | 5.32 ± 1.82 |
Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. Collected on Day 3.
| hours | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 1.93 (1.70 to 2.17) |
| Voriconazole | 1.74 (1.67 to 2.05) |
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole; measured as micrograms times hours per milliliter (ug\*hr/mL). Collected on Day 3.
| ug*hr/mL | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 101 ± 21.8 |
| Voriconazole | 39.5 ± 19.8 |
t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Collected on Day 3.
| hours | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin (n=18) | 20.8 ± 3.06 |
| Voriconazole (n=15) | 6.94 ± 2.10 |
CL total = total clearance calculated as dose divided by AUCt; measured as milliliters per minute (mL/min). Collected on Day 3.
| mL/min | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 17.1 ± 3.04 |
| Voriconazole | 172 ± 86.2 |
Vss = volume of distribution at steady-state; measured as liters (L). Calculated as (CL multiplied by mean residence time extrapolated to infinity \[MRTinf\]). MRTinf = \[(AUMCt plus t (AUCinf minus AUCt)) divided by AUCt\] minus (infusion time divided by 2); AUMCt = area under the first moment curve from time zero to time t; AUCinf = area under the plasma concentration-time curve extrapolated to infinity.
| L | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin (n=18) | 30.8 ± 6.84 |
| Voriconazole (n=15) | 110 ± 34.0 |
Cmax=maximum observed plasma concentration. ELF collected by bronchoscopy and bronchoalveolar lavage (BAL) Day 3; determined from BAL sample using urea dilution method: \[Drug ELF\]=\[Drug BAL\] multiplied by \[Urea SERUM\] divided by \[Urea BAL\]. Drug ELF=anidulafungin or voriconazole (drug) concentration in ELF corrected for dilution; Drug BAL=assayed drug concentration in BAL; Urea SERUM and Urea BAL simultaneously collected. Summary parameters derived using average data for all subjects; associated to a single subject for reporting purposes (mean with standard deviation not calculated).
| average concentration (ug/mL) | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 1.13 |
| Voriconazole | 48.3 |
Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. ELF collected by bronchoscopy and BAL on Day 3.
| hours | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 24.0 |
| Voriconazole | 4.0 |
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. ELF collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
| average concentration (ug*hr/mL) | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 21.9 |
| Voriconazole | 282 |
t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. ELF collected by bronchoscopy and BAL on Day 3.
No measurements were reported for this outcome.
Cmax = maximum observed plasma concentration; observed directly from the data. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
| average concentration (ug/mL) | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 103 |
| Voriconazole | 20.5 |
Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. AM collected by bronchoscopy and BAL on Day 3.
| hours | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 24 |
| Voriconazole | 4.0 |
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
| average concentration (ug*hr/mL) | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 1430 |
| Voriconazole | 178 |
t1/2 = terminal elimination half-life in hours; Loge(2)Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AM collected by bronchoscopy and BAL on Day 3.
No measurements were reported for this outcome.
ELF collected by bronchoscopy and BAL on Day 3. ELF to plasma penetration ratio calculated by dividing area under the plasma concentration-time profile (AUC) in ELF by AUC in plasma from 20 subjects where t is 24 hours for anidulafungin and 12 hours for voriconazole. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
| average ELF to plasma ratio | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin | 0.22 |
| Voriconazole | 7.14 |
Concentration ratio in ELF to plasma determined by a point estimate within each subject at the time-point where ELF data was available.
| ratio | Anidulafungin and Voriconazole |
|---|---|
| Anidulafungin 4 hours | 0.15 ± 0.02 |
| Anidulafungin 8 hours | 0.15 ± 0.07 |
| Anidulafungin 12 hours | 0.20 ± 0.09 |
| Anidulafungin 24 hours | 0.38 ± 0.14 |
| Voriconazole 4 hours | 9.50 ± 2.31 |
| Voriconazole 8 hours | 4.93 ± 2.79 |
| Voriconazole 12 hours | 7.68 ± 3.41 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anidulafungin and Voriconazole | — | 0/21 (0%) | 15/21 (71.4%) |
| Event | Anidulafungin and Voriconazole |
|---|---|
| HeadacheNervous system disorders | 6/21 |
| Influenza like illnessGeneral disorders | 4/21 |
| Visual impairmentEye disorders | 3/21 |
| PhotophobiaEye disorders | 2/21 |
| VomitingGastrointestinal disorders | 2/21 |
| NauseaGastrointestinal disorders | 1/21 |
| HypersensitivityImmune system disorders | 1/21 |
| Liver function test abnormalInvestigations | 1/21 |
| Hallucination, visualPsychiatric disorders | 1/21 |
| InsomniaPsychiatric disorders | 1/21 |
| Age Continuous(years) | Anidulafungin and Voriconazole |
|---|---|
| Mean | 27.3 ± 7.8 |
| Sex: Female, Male(Participants) | Anidulafungin and Voriconazole |
|---|---|
| Female | 5 |
| Male | 19 |
The record gives a start of Sep 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anidulafungin · Voriconazole